Illumina Stock News

Since the late 1970s, when the former options trader and arbitrageur moved into activist investing (then called “corporate raiding”), Carl Icahn has built a multi-billion dollar fortune investing

In reproductive health, Illumina (ILMN) primarily focuses on driving noninvasive prenatal testing (NIPT) adoption globally.

Illumina (ILMN) Q4 revenues increase year over year, driven by NovaSeq X instrument and consumables sales.

Illumina, Inc. (ILMN) Q4 2023 Earnings Call Transcript

While the top- and bottom-line numbers for Illumina (ILMN) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compa

Illumina on Thursday forecast its annual core business revenue to be nearly flat compared to fiscal year 2023 as subdued demand for its genetic testing tools and diagnostics products extends into this

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and Illumina (ILMN). But which of these two stocks present

Healthcare stocks are one part of the stock market that has a lot of room to grow until 2024. The healthcare industry is growing because of the growing focus on health and well-being around the world

I'm bullish on the long-term trajectory of personalized medicine stocks. These companies specialize in tailoring a holistic approach to healthcare, with medical treatments tailored to the individual c

Blood tests for dozens of types of cancer have been invented. These tests, known as liquid biopsies, could save tens of millions of lives.

With so many question marks facing the viability of the equities sector, concerned investors may want to turn their attention to compelling healthcare stocks. Primarily, the sector benefits from perma

Illumina's (ILMN) fourth-quarter 2023 results are likely to reflect the impacts of the adoption of its new generation of distributed liquid biopsy assay.

Competition is what makes markets work (when they do). But firms don't like competition because it tends to drive down profits.

The beaten-down stock got a couple of analyst upgrades. Illumina also confirmed it would sell Grail, its controversial 2021 acquisition.

Illumina (ILMN) aims to work with other pharmaceutical industry leaders to enhance and expand the utility of its WGS MRD assay.